The abstract is read at the publisher; the summary is JClub's.
Entinostat treatment in Myc-driven SCLC tumors shifts tumors from a neuroendocrine-high to neuroendocrine-low phenotype and increases T-cell infiltration in RPM mice.
- Why it matters: SCLC is highly aggressive and often low in immunogenicity, so epigenetic immune evasion may limit responses to immunotherapy.
- What they did: The study tested entinostat, a class I histone deacetylase inhibitor, by measuring immune-related gene upregulation in human SCLC cells and immune checkpoint ligand/antigen presentation changes in Rb1/Trp53/MycT58A (RPM) SCLC mice.
- The result: In RPM allograft models, combining entinostat with anti-PD-1 suppresses tumor growth and significantly prolongs survival, supporting improved efficacy of checkpoint blockade.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.